Fox E, et al. Final results of a placebo controlled, Phase 2 multicenter study of ublituximab (UTX), a novel glycoengineered anti-CD20 monoclonal antibody (mAb), in patients with relapsing forms of multiple sclerosis (RMS). ECTRIMS 2018, abstract 229.
Trombectomie verbetert functionele uitkomsten bij beroerte met groot infarct op CT zonder contrast niet
nov 2024 | Neuro-vasculair